– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –
– Preclinical data and U.S.Read More
You might also be interested in reading MakerDAO Invests Hefty Amount Becoming The Largest Stake Holder In USDC.